Markel Group Inc. Has $7.82 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Markel Group Inc. lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 15.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,642 shares of the medical research company’s stock after selling 9,084 shares during the period. Markel Group Inc.’s holdings in IQVIA were worth $7,823,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mather Group LLC. boosted its position in IQVIA by 83.5% during the first quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 350 shares during the last quarter. Verdence Capital Advisors LLC acquired a new stake in IQVIA during the second quarter valued at $3,612,000. Patton Fund Management Inc. acquired a new stake in IQVIA during the second quarter valued at $231,000. Private Advisor Group LLC boosted its position in IQVIA by 11.6% during the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock valued at $958,000 after purchasing an additional 566 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after purchasing an additional 606,391 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

NYSE IQV opened at $218.26 on Wednesday. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $225.91. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market capitalization of $37.10 billion, a PE ratio of 31.59, a P/E/G ratio of 2.39 and a beta of 1.32. The stock has a 50-day simple moving average of $195.48 and a 200 day simple moving average of $172.51.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the previous year, the firm earned $2.84 EPS. The firm’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on IQV. Mizuho lifted their price objective on IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Evercore ISI lifted their price objective on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday, September 3rd. Truist Financial lifted their price objective on IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Finally, UBS Group boosted their price target on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $234.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.